Takeda Releases Narcolepsy Treatment ORZEYFUL
The drug is now available in Japan and China, with a United States launch scheduled for next month.
Updated on Oct. 15, 2026 in Sleep Disorders
Live Poll
Do you believe new pharmaceutical breakthroughs effectively improve the daily quality of life for patients?
Takeda has officially released ORZEYFUL, an oral medication designed to treat narcolepsy type 1. The drug is currently available in Japan and China following regulatory approval.
Why it matters
Narcolepsy type 1 is a chronic condition caused by orexin deficiency, and ORZEYFUL addresses this by stimulating orexin receptor 2. The therapy aims to restore signaling to help patients manage symptoms effectively.
Phase 3 clinical studies conducted over 12 weeks showed significant improvements in wakefulness and reductions in cataplexy compared to placebo. In China, the medication is approved for patients aged 16 and older.
The players
Takeda
Takeda is a global pharmaceutical company with corporate offices located in Cambridge, Massachusetts.
Japan's Ministry of Health, Labour and Welfare
This agency is the governmental body responsible for public health and the approval of new medical treatments in Japan.
China's National Medical Products Administration
This regulatory authority oversees the safety and approval of pharmaceuticals and medical devices within China.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of human drugs in the United States.
The details
Administered as a tablet, ORZEYFUL functions as an orexin receptor 2 agonist to restore essential signaling in the brain. Reported side effects associated with the treatment include insomnia, urinary urgency, urinary frequency, and excessive saliva.
Timeline
June 14-17, 2026: Phase 3 trial results were presented at SLEEP 2026.
October 15, 2026: Takeda announced the availability of ORZEYFUL.
November 2026: ORZEYFUL is scheduled for launch in the U.S.
The Big Picture
The introduction of ORZEYFUL follows the dissemination of key clinical data at the SLEEP 2026 conference. This launch represents a significant step in the treatment of chronic narcolepsy type 1 by restoring essential neurological signaling.
Patients with narcolepsy type 1 may now have access to a new oral treatment option that focuses on restoring orexin signaling. Individuals considering the medication should be aware of potential side effects including urinary changes and insomnia.
The takeaway
ORZEYFUL offers a targeted approach for managing the symptoms of narcolepsy type 1 through orexin receptor stimulation. Patients should consult with their healthcare providers to discuss whether this new therapy is appropriate for their specific clinical needs.
What happens next
ORZEYFUL is scheduled to launch in the United States in November 2026.
Further reading
For more information on current treatment options, visit the Sleep Disorders section.
More information
Learn more about the therapy on the Takeda company website.
Live Poll
Do you believe new pharmaceutical breakthroughs effectively improve the daily quality of life for patients?
